These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31907330)

  • 21. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
    Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
    J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
    Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
    Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Toward Preclinical Trials for Alzheimer's Disease].
    Miyagawa T; Iwatsubo T
    Brain Nerve; 2017 Jul; 69(7):711-722. PubMed ID: 28739984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease.
    Schneider LS
    Alzheimers Dement; 2014 Mar; 10(2):247-50. PubMed ID: 24698029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early-stage Alzheimer disease: getting trial-ready.
    Aisen PS; Jimenez-Maggiora GA; Rafii MS; Walter S; Raman R
    Nat Rev Neurol; 2022 Jul; 18(7):389-399. PubMed ID: 35379951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.
    Boxer AL; Sperling R
    Cell; 2023 Oct; 186(22):4757-4772. PubMed ID: 37848035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.